Investigational Drug Information for Plinabulin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Plinabulin?
Plinabulin is an investigational drug.
There have been 10 clinical trials for Plinabulin.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 29th 2018.
The most common disease conditions in clinical trials are Lung Neoplasms, Neutropenia, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., Lyudmila Bazhenova, M.D., and National Cancer Institute (NCI).
There are thirty-seven US patents protecting this investigational drug and two hundred and eighty-seven international patents.
Summary for Plinabulin
| US Patents | 37 |
| International Patents | 287 |
| US Patent Applications | 165 |
| WIPO Patent Applications | 110 |
| Japanese Patent Applications | 36 |
| Clinical Trial Progress | Phase 3 (2018-05-29) |
| Vendors | 50 |
Recent Clinical Trials for Plinabulin
| Title | Sponsor | Phase |
|---|---|---|
| Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | BeyondSpring Pharmaceuticals Inc. | Phase 2 |
| Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
Clinical Trial Summary for Plinabulin
Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin
US Patents for Plinabulin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Plinabulin | See Plans and Pricing | Method of treating a brain tumor | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | See Plans and Pricing |
| Plinabulin | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Plinabulin | See Plans and Pricing | Nanoparticle formulations for delivering multiple therapeutic agents | AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Plinabulin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Plinabulin | Australia | AU2016229295 | 2035-03-06 | See Plans and Pricing |
| Plinabulin | Australia | AU2021254549 | 2035-03-06 | See Plans and Pricing |
| Plinabulin | Brazil | BR112017018964 | 2035-03-06 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
